The items as outlined in the CRL need to be addressed prior to a resubmission:
In December 2021, MSB announced the following:
[...]
https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02472385-3A584817?access_token=83ff96335c2d45a094df02a206a39ff4
In May 2022, they then announced that in addition to that new data generated (54-patient Phase 3 trial plus the comparison with 27 closely matched children from the Mount Sinai Acute GVHD International Consortium):
That data plus the above is to be submitted to the FDA:
https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02527306-3A594692?access_token=83ff96335c2d45a094df02a206a39ff4
SI now stated that this has been done:
https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02576759-3A603647?access_token=83ff96335c2d45a094df02a206a39ff4
Why "NEW INFORMATION TO FDA IND FILE" - because that's what deals with CMC and is the backbone of any future trial using this (remestemcel-L) product, i.e. in ARDS:
https://www.fda.gov/drugs/investigational-new-drug-ind-application/ind-applications-clinical-investigations-chemistry-manufacturing-and-control-cmc-information
It is important to note that CBER has not considered "the adequacy of the clinical data
in the context of the related CMC issues" just yet. That will happen once the resubmission is accepted as mentioned above.
Next step: BLA resubmission.
- Forums
- ASX - By Stock
- MSB
- Ann: Submits New Information to FDA IND File for SR-aGVHD
Ann: Submits New Information to FDA IND File for SR-aGVHD, page-237
-
-
- There are more pages in this discussion • 340 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
94.0¢ |
Change
-0.020(2.08%) |
Mkt cap ! $1.073B |
Open | High | Low | Value | Volume |
95.5¢ | 97.0¢ | 93.5¢ | $1.424M | 1.507M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 29390 | 93.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
94.5¢ | 14089 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 29390 | 0.935 |
12 | 175098 | 0.930 |
7 | 101559 | 0.925 |
8 | 126323 | 0.920 |
10 | 99179 | 0.915 |
Price($) | Vol. | No. |
---|---|---|
0.945 | 14089 | 2 |
0.950 | 32015 | 3 |
0.955 | 49989 | 4 |
0.960 | 32869 | 2 |
0.965 | 35384 | 2 |
Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online